PJ Online | News | DTB gives cautious welcome to second-line use of two newer antifungal agents ... but criticises transdermal contraceptive patch website
The Pharmaceutical Journal
DTB gives cautious welcome to second-line use of two newer antifungal agents ...
Voriconazole (Vfend), a new triazole antifungal agent, is a reasonable choice for second-line treatment against systemic fungal infections, according to the Drug and Therapeutics Bulletin (2004;42:5). However, the DTB is not convinced by the claim that this drug is superior to amphotericin B at increasing survival rates in patients with invasive aspergillosis.
... but criticises transdermal contraceptive patch website
Evra, the new contraceptive patch, is twice as likely to be discontinued because of unwanted effects as the combined oral contraceptive, according to the Drugs and Therapeutics Bulletin (2003;41:89). It has also criticised the way Janssen-Cilag has promoted the product on a specially designed website.
Citation: The Pharmaceutical Journal URI: 20011000
Recommended from Pharmaceutical Press